Vol. IX | Issue 41                                                                               October 13, 2020
Surprise Move by HCA: $6B in COVID Aid to Be Returned
Rebecca Pifer reports for Healthcare Dive:

HCA plans to return all the federal COVID-19 relief it's received since the beginning of the pandemic, the Nashville-based for-profit operator said Thursday, suggesting the hospital sector could be recovering from the worst of COVID-19's financial effects. The system, one of the largest in the U.S., is returning some $1.6 billion in federal COVID-19 relief grants and $4.4 billion in accelerated Medicare loans it received as part of the sweeping Coronavirus Aid, Relief and Economic Security Act, following a strong third quarter and cost control efforts. The move comes as major hospital groups continue to lobby for more relief amid the ongoing pandemic. But another piece of COVID-19 aid legislation is highly unlikely amid Washington gridlock and the looming November presidential election.
Florida DOH
COVID-19 frequently causes neurological injuries
ScienceDaily reports: 
Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows. These injuries range from temporary confusion due to low body-oxygen levels, to stroke and seizures in the most serious cases, say the study authors.  
Led by researchers at NYU Grossman School of Medicine, the study showed no cases of brain or nerve inflammation (meningitis or encephalitis), indicating no immediate invasion of these organs by the pandemic virus, SARS-CoV-2.  
While this should reassure patients, the neurological complications of COVID-19 should be taken seriously because they dramatically raise a patient's risk of dying while still in hospital... 
As Trump Touts His 'Great' COVID Drugs, the Pharma Cash Flows to Biden, Not Him 
Jay Hancock

Pharmaceutical giants Regeneron and Gilead Sciences got the kind of publicity money can't buy this week after President Donald Trump took their experimental drugs for his coronavirus infection, left the hospital and pronounced himself fully recovered.

"It was, like, unbelievable. I felt good immediately," Trump said Wednesday in a tweeted video. "I call that a cure."

He praised Regeneron's monoclonal antibody cocktail, which mimics elements of the immune system, and mentioned a similar drug under investigation by Eli Lilly and Co. The president also took Gilead's remdesivir, an antiviral that has shortened recovery times for COVID-19 patients in early research.

There is no scientific evidence that any of these drugs contributed to the president's recovery, since many patients do fine without them. It is also not known whether the president has been "cured," since the White House has released few specifics about the course of his illness.
Video Feature 
Physicians develop test to predict mild or severe COVID-19 symptoms
Physicians develop test to predict mild or severe COVID-19 symptoms 
WKMG News 6 Orlando
This is the presidential candidate more healthcare execs believe would be better for the industry: survey
Tina Reed reports for Fierce Healthcare:

When it comes to who healthcare executives want to see win the upcoming presidential election, it seems they are nearly as divided as average Americans.

In a recent survey by healthcare consulting firm Advis, about 46% of healthcare executive respondents said they believe a President Donald Trump and Vice President Mike Pence administration is better for the future of healthcare in the U.S. In comparison, just over 41% of the 130 executives who responded to the survey said they thought a win by former Vice President Joe Biden and California Sen. Kamala Harris would be better for the industry.

About 13% said they were still undecided in the survey, which was conducted in mid-September.